NCT04086121View on ClinicalTrials.gov

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

April 28, 2021

Study Completion Date

February 23, 2022

Conditions
Dermatitis, Atopic
Interventions
DRUG

Spesolimab

Solution for SC injection

Trial Locations (10)

33126

Finlay Medical Research Corp, Miami

33613

ForCare Clinical Research, Inc., Tampa

33912

Clinical Physiology Associates, Fort Myers

46168

The Indiana Clinical Trials Center, PC, Plainfield

73118

Unity Clinical Research, Oklahoma City

75230

Dermatology Treatment and Research Center, PA, Dallas

85260

CCT Research, Scottsdale

H2X 2V1

Innovaderm Research Inc., Montreal

240-0004

Tennocho Ekimae Dermatology and Allergology, Kanagawa, Yokohama

193-0998

Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04086121 - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 | Biotech Hunter | Biotech Hunter